A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Recruiting · NCT04993690 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-09-14 | NCT04993690 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Lupeng Pharmaceutical Company LTD. | 12 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | 208 |
| Peking University Third Hospital | Beijing | China | 4 |
| Sun Yat-sen University Cancer Center | Guangzhou | China | 315 |